106850-34-4

Basic information

• Product Name: IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE
• Synonyms: IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE;Imidazo[1,2-a]pyridine-6-carbonitrile 97%;iMidazo[1,2-a]pyridin-6-carbonitrile;6-CyanoiMidazo[1,2-a]pyridine, 95%;IMidazo[1,2-α]pyridine-6-carbonitrile;6-imidazo[2,1-f]pyridinecarbonitrile;imidazo[2,1-f]pyridine-6-carbonitrile;Imidazo[1,2-a]pyridine-6-carbonitrile97%
• CAS NO: 106850-34-4
• Molecular Formula: C₈H₅N₃
• Molecular Weight: 143.15
• Mol File: 106850-34-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 160-163
• Appearance: /
• Density: 1.22 g/cm³
• Refractive Index: 1.664
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.35±0.50(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE(106850-34-4)
• EPA Substance Registry System: IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE(106850-34-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 106850-34-4(Hazardous Substances Data)

Usage

General Description

IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE is a chemical compound with a molecular formula C7H4N4. It is a heterocyclic compound that contains both imidazole and pyridine rings. IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE is commonly used in pharmaceutical research and drug discovery. It acts as a building block for the synthesis of various biologically active molecules and potential drug candidates. IMIDAZO[1,2-A]PYRIDINE-6-CARBONITRILE is known for its diverse pharmacological activities, including antiviral, anticancer, and antibacterial properties. Its unique structural features make it a valuable component in the development of new therapeutic agents for various medical conditions.

InChI:InChI=1/C8H5N3/c9-5-7-1-2-8-10-3-4-11(8)6-7/h1-4,6H

Upstream product

• 103313-38-8 imidazo[1,2-a]pyridine-6-carboxamide 
• 107-20-0 2-chloroethanal 
• 4214-73-7 6-aminonicotinonitrile 
• 1235991-09-9 N'-(5-cyano-pyridin-2-yl)-N,N-dimethylformamidine 
• 24517-64-4 2-amino-3-pyridinecarbonitrile 

Downstream Products

• 1313726-32-7 3-(Hydroxymethyl)imidazo[1,2-a]pyridine-6-carbonitrile 
• 132213-03-7 imidazo<1,2-a>pyridin-6-ylmethylamine 
• 1313723-21-5 6-(4-fluorophenyl)-1-(imidazo[1,2-a]pyridin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine 
• 1373494-62-2 3-(4-formylphenyl)-imidazo[1,2-a]pyridine-6-carbonitrile 
• 1313007-12-3 3-{4-[benzyl(methyl)amino]pyrimidin-2-yl}imidazo[1,2-a]pyridine-6-carbonitrile 
• 1313007-46-3 3-(4-{[(3R)-1-(4-cyano-2-fluorophenyl)piperidin-3-yl]amino}pyrimidin-2-yl)imidazo[1,2-a]pyridine-6-carbonitrile 

Relevant articles and documents

Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases

Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34, a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).